Search

Search Results
Results 1051 - 1060 of 1163 for Diabetes Type II
  • LCT receives approval for New Zealand Phase II human trial of DIABECELL
    News - 30 Mar 2010
    Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New...
  • Norwegian government task force suggests formation of single company to commercialise biomaterial assets
    News - 18 Feb 2010
    Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets...
  • Merck announces global sales of $27.4 billion for full-year 2009
    News - 16 Feb 2010
    Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov....
  • Cymbalta (duloxetine HCl) shown to delay new episodes of depression
    News - 14 Dec 2008
    New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had...
  • Olmesartan HCT Viatris
    Drug - 29 Sep 2026
    Consumer Medicine Information (CMI) about Olmesartan HCT Viatris intended for persons living in Australia.
  • Tarka
    Drug - 24 Sep 2026
    Consumer Medicine Information (CMI) about Tarka intended for persons living in Australia.
  • Eleva
    Drug - 23 Sep 2026
    Consumer Medicine Information (CMI) about Eleva intended for persons living in Australia.
  • Zedace
    Drug - 3 Sep 2026
    Consumer Medicine Information (CMI) about Zedace intended for persons living in Australia.
  • Symdeko
    Drug - 26 Aug 2026
    Consumer Medicine Information (CMI) about Symdeko intended for persons living in Australia.
  • Skyclarys
    Drug - 24 Aug 2026
    Consumer Medicine Information (CMI) about Skyclarys intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback